ResMed (RMD) – Investment Analysts’ Weekly Ratings Changes

ResMed (NYSE: RMD) recently received a number of ratings updates from brokerages and research firms:

• 5/1/2026 – ResMed was given a new $225.00 price target by Robert W. Baird.
• 5/1/2026 – ResMed had its price target raised by Royal Bank Of Canada from $314.00 to $321.00. They now have an “outperform” rating on the stock.
• 5/1/2026 – ResMed had its price target lowered by Wells Fargo & Company from $270.00 to $227.00. They now have an “equal weight” rating on the stock.
• 4/27/2026 – ResMed had its price target lowered by KeyCorp from $302.00 to $290.00. They now have an “overweight” rating on the stock.
• 4/15/2026 – ResMed is now covered by JPMorgan Chase & Co.. They set an “overweight” rating on the stock.
• 4/13/2026 – ResMed was given a new $255.00 price target by Evercore Inc. They now have an “outperform” rating on the stock.
• 4/9/2026 – ResMed had its price target lowered by Citigroup Inc. from $345.00 to $340.00. They now have a “buy” rating on the stock.
• 3/19/2026 – ResMed was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
• 3/14/2026 – ResMed was downgraded by Wall Street Zen from “buy” to “hold”.

ResMed Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 18th. Investors of record on Thursday, May 14th will be issued a $0.60 dividend. The ex-dividend date is Thursday, May 14th. This represents a $2.40 dividend on an annualized basis and a yield of 1.1%. ResMed’s dividend payout ratio is currently 23.14%.

Insiders Place Their Bets

In related news, CEO Michael J. Farrell sold 4,991 shares of the company’s stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of $225.50, for a total value of $1,125,470.50. Following the completion of the sale, the chief executive officer directly owned 466,223 shares in the company, valued at approximately $105,133,286.50. This represents a 1.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter C. Farrell sold 2,000 shares of the company’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $225.00, for a total transaction of $450,000.00. The disclosure for this sale is available in the SEC filing. Insiders sold 18,973 shares of company stock valued at $4,715,237 over the last quarter. 0.65% of the stock is currently owned by corporate insiders.

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.